Table 7.
Author, year of publication | Primary outcomes | Secondary outcomes | ||||
---|---|---|---|---|---|---|
Flap dehiscence | Membrane exposure (GTR treated sites) | Suppuration | Abscess formation | Swelling | Allergic reaction | |
A. Sculean et al. 1999a [56] | – | 7/16 GTR sites (3 w) | No | No | 7/16 EMD sites 8/16 GTR sites (first w) | No |
A. Sculean et al. 1999b [60] | – | No | No | No | – | No |
N. Donos et al. 2004 [62] | – | 2/3 GTR sites (BM alone), 5/7 GTR sites (BM + EMD) (first 2 w) | – | No | – | No |
P. Cortellini et al. 2005 [57] | 2/11 GTR sites (BM + BG), 1/7 GTR sites (BM alone) 1/10 EMD sites (1–2 w) | – | – | – | – | – |
A. Crea et al. 2008 [61] | 3/20 GTR sites 2/19 EMD sites (5–6 days) | – | – | No | No | No |
V. Iorio-Siciliano et al. 2011 [58] | – | 3/20 GTR sites (5 w) | – | – | – | – |
V. Iorio-Siciliano et al. 2014 [59] | – | 4/20 GTR sites (1 w) | – | – | – | – |
BM bioabsorbable membrane, BG bone graft, EMD enamel matrix derivate, GTR guided tissue regeneration, w week